Procept Biorobotics's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Procept Biorobotics (PRCT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Procept Biorobotics vs Its Competitors
- TTM: Trailing 12-month revenue of 337M vs 280,218M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+12.2% annualized vs trailing 12 months), vs accelerating (+2.2%) for its tracked peer group.
- Growth: Procept Biorobotics generated 20.0% revenue growth year over year in Q2 2026, vs 9.7% for its competitors combined.
- Profitability: Its -28.4% net margin compares with 16.1% for the peer group.
- Scale: Procept Biorobotics ranks #68 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.1% of industry market cap.
- Peer revenue share: Procept Biorobotics accounted for 0.1% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.38M compares with $0.41M for the peer group (0.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PRCT Sales vs. its Competitors, Q2 2026
Procept Biorobotics reported revenue growth of 20.00 % year on year in Q2 2026, above its competitors' combined revenue growth of 9.74 %.
With a net margin of -28.42 %, Procept Biorobotics reported lower profitability than its competitors (16.05 %).
Procept Biorobotics generated 0.13 % of the combined sales of its peer group, up from 0.12 % a year earlier.
Procept Biorobotics vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Procept Biorobotics reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Procept Biorobotics and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Procept Biorobotics Corporation | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Procept Biorobotics's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.5% year over year, combined, vs 20.0% for Procept Biorobotics. Procept Biorobotics's share of combined industry revenue moved from 0.08% to 0.08%, a gain of 0.00 percentage points.
Procept Biorobotics's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Procept Biorobotics Corporation | No | Yes | Yes | No |
| Competitors combined (42) | ||||
| High-Confidence Competitors (2) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PRCT Stock Performance relative to its Competitors
PRCT Stock Performance relative to High-Confidence Competitors
PRCT Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Axogen inc | 282.9% | Outperformed |
| 2 | Monogram technologies inc | 282.9% | Outperformed |
| 3 | Orthopediatrics Corp | 282.9% | Outperformed |
| 4 | Bioventus Inc | 282.9% | Outperformed |
| 5 | Livanova Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Procept Biorobotics's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Procept Biorobotics's Comment on Competition and Industry Peers
Publicly Traded Peers of Procept Biorobotics Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Procept Biorobotics Corporation |
1,236.07 | 336.76 |
 Johnson and Johnson |
676,597.15 | 99,335.00 |
 Intuitive Surgical Inc |
169,506.36 | 12,115.60 |
 Medtronic Plc |
134,884.10 | 37,542.00 |
 Stryker Corp |
130,663.35 | 26,300.00 |
 Boston Scientific Corporation |
66,530.64 | 21,070.00 |
| SUBTOTAL | 1,404,059.36 | 287,192.64 |
Sign in to see all competitors of Procept Biorobotics Corporation.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Procept Biorobotics Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Procept Biorobotics's Competitors Named by the Company
Competitive relationships identified from Procept Biorobotics reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Boston Scientific Corporation | Company report | 85% |
| Teleflex Incorporated | Company report | 85% |
| Flex Ltd | Company report | 85% |
| Utah Medical Products Inc | Company report | 85% |
| Angiodynamics Inc | Company report | 85% |
| Silk Road Medical Inc | Company report | 85% |
| Intuitive Surgical Inc | Company report | 85% |
| Lemaitre Vascular Inc | Company report | 85% |
| Medtronic Plc | Company report | 85% |
| Vaso Corporation | Company report | 85% |
| Merit Medical Systems Inc | Company report | 85% |
| Atrion Corporation | Company report | 85% |
| Encision Inc | Company report | 85% |
| Conformis inc | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
| Alphatec Holdings Inc | Company report | 85% |
| Surgalign Holdings Inc | Company report | 85% |
| Vicarious Surgical Inc | Company report | 85% |
| Nuvasive Inc | Company report | 85% |
| Conmed Corporation | Company report | 85% |
| Inari Medical Inc | Company report | 85% |
| Si bone inc | Company report | 85% |
| Orthopediatrics Corp | Company report | 85% |
| Asensus Surgical Inc | Company report | 85% |
| Bioventus Inc | Company report | 85% |
| Livanova Plc | Company report | 85% |
| Enovis Corp | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Orthofix Medical Inc | Company report | 85% |
| Streamex Corp | Company report | 85% |
| Medinotec Inc | Company report | 85% |
| Bone Biologics Corporation | Company report | 85% |
| Adagio Medical Holdings inc | Company report | 85% |
| Stryker Corp | Company report | 85% |
| Paragon 28 inc | Company report | 85% |
| Fuse Medical Inc | Company report | 85% |
| Axogen inc | Company report | 85% |
| Monogram technologies inc | Company report | 85% |
| Smith and Nephew Plc | Company report | 85% |
| Zimvie Inc | Company report | 85% |
| Globus Medical Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Procept Biorobotics's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Procept Biorobotics's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Johnson and Johnson | Oncology 29.93 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 56.20 % |
| Boston Scientific Corporation | Cardiovascular 66.29 % |
| Becton Dickinson And Company | Medical Essentials 34.94 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Procept Biorobotics Corporation.
Procept Biorobotics's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Procept Biorobotics Corporation | 1,236 | 379,239 | -123,599 |
| Johnson and Johnson | 676,597 | 705,504 | 114,311 |
| Intuitive Surgical Inc | 169,506 | 711,803 | 174,578 |
| Medtronic Plc | 134,884 | 395,179 | 55,463 |
| Stryker Corp | 130,663 | 469,643 | 64,696 |
| Boston Scientific Corporation | 66,531 | 357,119 | 59,220 |
| PEERS TOTAL | 1,402,823 | 412,223 | 48,725 |
Sign in to see all peers for Procept Biorobotics Corporation.
Procept Biorobotics's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Procept Biorobotics Corporation | United States 86.82 % |
| Johnson and Johnson | United States 58.90 % |
| Intuitive Surgical Inc | Geographic Distribution, Foreign 29.66 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.92 % |
| Boston Scientific Corporation | United States 64.40 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Procept Biorobotics Corporation.
Procept Biorobotics's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Procept Biorobotics's industry classification, broader than the peer set above. Market cap in millions of $.Procept Biorobotics ranks #68 of 218 companies by market capitalization in its industry, holding 0.10 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 620, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 172,254 | 13.84 % |
| 2 | Medtronic Plc | 134,884 | 10.84 % |
| 3 | Stryker Corp | 131,105 | 10.53 % |
| 4 | 3m Company | 101,319 | 8.14 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Medline Inc | 1,234 | 5.2% |
| 68 | Procept Biorobotics Corporation | 1,236 | 0.10 % |
Market cap and industry share for the rest of Procept Biorobotics's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-04.
Procept Biorobotics's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 63 | Innovage Holding Corp | 1,328 | 108.35 % |
| 64 | Tandem Diabetes Care Inc | 1,315 | 31.06 % |
| 65 | Alphatec Holdings Inc | 1,296 | -59.51 % |
| 66 | Artivion Inc | 1,284 | -44.28 % |
| 67 | Omada Health Inc | 1,234 | 12.3% |
| 68 | Procept Biorobotics Corporation | 1,236 | -37.00 % |
| 69 | Integra Lifesciences Holdings Corp | 1,234 | 12.3% |
| 70 | Iradimed Corporation | 1,234 | 12.3% |
| 71 | Alpha Tau Medical Ltd | 1,234 | 12.3% |
| 72 | Si bone inc | 1,234 | 12.3% |
| 73 | Ceribell Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Procept Biorobotics's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-04. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Procept Biorobotics's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (345 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.64 % | 41.55 % (avg) | -40.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.46 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 3.14 % | 7.29 % (avg) | -4.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Procept Biorobotics's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 38.2x | - |
| EV / EBITDA | - | 18.1x | - |
| P/B | 4.0x | 4.6x | -0.6x |
| Return on Equity | -0.31 % | industry aggregate | -12.29 % |
| Return on Invested Capital | - | -5.79 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Procept Biorobotics's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | 81.36 % | 64.72 % | 37.09 % |
| Operating Margin | - | -107.61 % | -80.24 % | -43.11 % | -33.81 % |
| Return on Invested Capital | - | -15.53 % | -19.94 % | -14.66 % | -12.03 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Procept Biorobotics's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Procept Biorobotics falls in the Dog quadrant: relative market share of 0.01x vs its largest competitor, in an industry growing revenue 8.7% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Procept Biorobotics's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 620 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 3.14 % vs industry average 7.29 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Procept Biorobotics's dedicated Suppliers and Customers pages, not here.
Procept Biorobotics's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Procept Biorobotics falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Procept Biorobotics's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+12.2% annualized vs trailing 12 months).
Weaknesses
- Return on equity 12.3 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.01x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Procept Biorobotics's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Procept Biorobotics Corporation | 4.27 | 7.08 | 0.14 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Intuitive Surgical Inc | 1.33 | 4.37 | - |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.50 | 2.08 | 0.65 |
| Boston Scientific Corporation | 0.23 | 1.50 | 0.46 |
Sign in to see all peers for Procept Biorobotics Corporation.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Procept Biorobotics's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Procept Biorobotics Corporation | Q2 2026 | +20.0 % | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Intuitive Surgical Inc | Q3 2026 | +32.7 % | -26.3 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q3 2026 | +7.6 % | -12.3 % |
| Boston Scientific Corporation | Q3 2026 | +1.4 % | -23.2 % |
| PEERS TOTAL | +9.2 % | -45.9 % |
Sign in to see all peers for Procept Biorobotics Corporation.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Procept Biorobotics's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Procept Biorobotics Corporation | Q2 2026 | +19.0 % | +5.4 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Intuitive Surgical Inc | Q3 2026 | +14.5 % | +7.3 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q3 2026 | +3.0 % | +26.7 % |
| Boston Scientific Corporation | Q3 2026 | +12.3 % | -0.6 % |
Sign in to see all peers for Procept Biorobotics Corporation.
Procept Biorobotics's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Procept Biorobotics Corporation | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Intuitive Surgical Inc | 14.71% | 16.30% | 16.99% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.66% | 8.63% | 15.61% |
| Boston Scientific Corporation | 7.82% | 9.14% | 13.75% |
Sign in to see all peers for Procept Biorobotics Corporation.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Procept Biorobotics's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Procept Biorobotics Corporation | - | 3.67 |
| Johnson and Johnson | 41.80 | 6.81 |
| Intuitive Surgical Inc | 58.51 | 13.99 |
| Medtronic Plc | 308.71 | 3.59 |
| Stryker Corp | 36.17 | 4.97 |
| Boston Scientific Corporation | 19.44 | 3.16 |
| PEERS AVERAGE | 41.54 | 4.89 |
Sign in to see all peers for Procept Biorobotics Corporation.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.